BioCorRx to Present at the H.C. Wainwright BioConnect 2022 Conference
BioCorRx Inc. (OTCQB: BICX) announced that CEO Lourdes Felix and President Brady Granier will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioCorRx Inc. (OTCQB: BICX) announced that CEO Lourdes Felix and President Brady Granier will present at the H.C. Wainwright BioConnect 2022 Conference, scheduled for January 10-13, 2022. The presentation will be available on-demand starting January 10, 2022, at 7:00 AM ET. BioCorRx is focused on innovative treatment solutions for substance abuse, including the Beat Addiction Recovery program and the UnCraveRx® Weight Loss Program. The company also seeks FDA approval for BICX104, an implantable naltrexone pellet for treating alcohol and opioid use disorders.
Details
News Market Reaction – BICX
The recorded move for BICX in the trading session of this news was +0.69%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ANAHEIM, CA, Jan. 05, 2022 (GLOBE NEWSWIRE) --
via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., and Brady Granier, President and Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc., will be presenting at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022.
BioCorRx’s presentation will be available on-demand to registered attendees via the conference platform beginning Monday, January 10, 2022 at 7:00 AM Eastern Time.
The webcast of the Company’s presentation can be accessed here: journey.ct.events and on the investor relations section of BioCorRx’s website at ir.biocorrx.com as of 7:00 AM Eastern Time on Monday, January 10, 2022.
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx's proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx® Weight Loss Program is also a medication assisted weight loss program that includes access to concierge on-demand wellness specialists: nutritionists, fitness experts and personal support from behavioral experts; please visit www.uncraverx.com for more information on UnCraveRx®. The Company also controls BioCorRx Pharmaceuticals, a clinical stage drug development subsidiary currently seeking FDA approval for BICX104, an implantable naltrexone pellet for treatment of alcohol and opioid use disorders. For more information on BICX and its subsidiary pipeline, please visit www.BioCorRx.com.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com
Media Contact:
CMW Media
(858) 264-6600
biocorrx@cmwmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.